



RESMED INC. ANNOUNCES EXCHANGE RATE FOR UPCOMING DIVIDEND PAYMENT

SYDNEY, February 21, 2014 – ResMed Inc. (NYSE: RMD and ASX: RMD) announced today that the exchange rate for the dividend to be paid on March 19, 2014 to holders of CHESS Depositary Instruments (CDIs) trading on the Australian Securities Exchange (ASX) will be \$0.9002 U.S. dollars for \$1.00 Australian dollar. The dividend to be paid in Australian currency to CDI holders will be \$0.02777 Australian dollars per CDI.

ResMed previously declared on January 24, 2013 a dividend of \$0.25 U.S. dollars per ResMed's common stock trading on the New York Stock Exchange (NYSE). The dividend will be paid in U.S. currency to holders of the common stock trading on the NYSE. Holders of CDIs trading on the ASX receive an equivalent amount in Australian currency, based on the exchange rate on the record date of February 19, 2014, and reflecting the 10:1 ratio between CDIs and NYSE shares.

About ResMed

ResMed is a global leader in the development, manufacturing and marketing of medical products for the diagnosis, treatment and management of respiratory disorders, with a focus on sleep-disordered breathing. The company is dedicated to developing innovative products to improve the lives of those who suffer from these conditions and to increasing awareness among patients and healthcare professionals of the potentially serious health consequences of untreated sleep-disordered breathing. For more information on ResMed, visit www.resmed.com.

Further information can be obtained by contacting David Pendarvis at ResMed Inc., San Diego, at (+1 858) 836-5983; Brett Sandercock at ResMed Limited, Sydney, on (02) 8884-2090; or by visiting the Company's multilingual website at www.resmed.com.

Statements contained in this release that are not historical facts are "forward-looking" statements as contemplated by the Private Securities Litigation Reform Act of 1995. These forward-looking statements, including statements regarding the Company's future revenue, earnings or expenses, new product development and new markets for the Company's products, are subject to risks and uncertainties, which could cause actual results to materially differ from those projected or implied in the forward-looking statements. Those risks and uncertainties are discussed in the Company's Annual Report on Form 10-K for its most recent fiscal year and in other reports the Company files with the U.S. Securities & Exchange Commission. Those reports are available on the Company's Website.

- End -